Search

Displaying results 3861 - 3870 of 4644 in total
  1. Drug

    Sagopilone

    go.drugbank.com/drugs/DB12391
    Investigational

    It is a so-called fully synthetic epothilone and is the first such compound to be in clinical development to combat several forms of cancer.

  2. Drug

    Otenabant

    go.drugbank.com/drugs/DB11745
    Investigational

    Otenabant has been investigated for the treatment of Obesity.

  3. Drug

    TST10088

    go.drugbank.com/drugs/DB05151
    Experimental

    TST10088 has been designed and engineered by Twinstrand to contain a peptide switch that is specifically cleaved by the matrix metalloproteinases which are known to be involved in tumor growth and metastasis

  4. Drug

    humanized SMART Anti-IL-12 Antibody

    go.drugbank.com/drugs/DB05848
    Experimental

    SMART Anti-IL-12 Antibody was humanized at PDL from a murine anti-IL-12 antibody that was licensed, together with certain intellectual property related to anti-IL-12 therapy, from Hoffmann-La Roche Inc

  5. Drug

    Ginsenoside Rg1

    go.drugbank.com/drugs/DB06750
    ExperimentalNutraceutical

    Rg1 Appears to be most abundant in Panax ginseng (Chinese/Korean Ginseng). It improves spatial learning and increase hippocampal synaptophysin level in mice, plus demonstrates estrogen-like activity.

  6. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    [L51419] Sparsentan was initially developed for the treatment of hypertension;[A257340] however, it has shown to be efficient in the reduction of proteinuria in patients with IgAN and focal segmental glomerulosclerosis

  7. Drug

    Tafasitamab

    go.drugbank.com/drugs/DB15044
    ApprovedInvestigational

    [L15307] It must be used in combination with [lenalidomide], as this combination results in greater efficacy as compared to either agent alone.[L15292]

  8. Drug

    Siagoside

    go.drugbank.com/drugs/DB12351
    Investigational

    Sygen appears to be beneficial in patients with severe spinal cord injury.

  9. Drug

    XL784

    go.drugbank.com/drugs/DB04991
    Investigational

    XL784 was specifically optimized to be MMP-1 sparing, thus potentially enhancing its safety profile and enabling higher dosing compared with other previously studied metalloprotease inhibitors.

  10. Drug

    Rucaparib

    go.drugbank.com/drugs/DB12332
    ApprovedInvestigational

    Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of a...